KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash from Investing Activities (2016 - 2022)

TherapeuticsMD (TXMD) has disclosed Cash from Investing Activities for 12 consecutive years, with -$74000.0 as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Cash from Investing Activities rose 95.11% year-over-year to -$74000.0, compared with a TTM value of -$355000.0 through Dec 2022, up 84.03%, and an annual FY2022 reading of -$355000.0, up 84.03% over the prior year.
  • Cash from Investing Activities was -$74000.0 for Q4 2022 at TherapeuticsMD, down from $7000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $7000.0 in Q3 2022 and bottomed at -$20.7 million in Q4 2019.
  • Average Cash from Investing Activities over 5 years is -$2.5 million, with a median of -$418500.0 recorded in 2020.
  • The sharpest move saw Cash from Investing Activities crashed 28077.04% in 2018, then surged 103.85% in 2022.
  • Year by year, Cash from Investing Activities stood at -$671171.0 in 2018, then plummeted by 2986.19% to -$20.7 million in 2019, then soared by 97.62% to -$494000.0 in 2020, then plummeted by 206.48% to -$1.5 million in 2021, then surged by 95.11% to -$74000.0 in 2022.
  • Business Quant data shows Cash from Investing Activities for TXMD at -$74000.0 in Q4 2022, $7000.0 in Q3 2022, and -$76000.0 in Q2 2022.